​​Now in effect: Preferred products for long-acting colony-stimulating factors

November 18, 2022

Effective November 1, 2022, the following long-acting colony-stimulating factors are designated as preferred products for members enrolled in Independence Administrators commercial programs and Independence Blue Cross commercial and Medicare Advantage programs:

  • Fulphila® (pegfilgrastim-jmdb)  
  • Neulasta® (pegfilgrastim)           
  • Ziextenzo® (pegfilgrastim-bmez)             

All other long-acting colony-stimulating factors are considered nonpreferred, including:

  • Fylnetra® (pegfilgrastim-pbbk)
  • Nyvepria® (pegfilgrastim-apgf)
  • Rolvedon™ (eflapegrastim-xnst)
  • Stimufend® (pegfilgrastim-fpgk)
  • Udenyca® (pegfilgrastim-cbqv)

The following medical policies are being updated to address these preferred and nonpreferred designations: